Drug therapy

Phase 2Small molecule

MMassachusetts General Hospital

Drug therapy is one of 147 small molecule programs targeting Adolescent. It is currently in Phase 2.

Indications

Total Trials

Active Trials

146

Competitors

Pipeline

Status by Indication[3][1]

Indication

AdolescentCompleted

EncephalopathyActive, not recruiting

Ischemic StrokeActive, not recruiting

Elderly PatientsRecruiting

NeuromodulationUnknown status

PneumoniaRecruiting

AdolescentPreclinical

Completed

EncephalopathyPreclinical

Active, not recruiting

Ischemic StrokePreclinical

Active, not recruiting

Elderly PatientsPhase 2

Recruiting

NeuromodulationPreclinical

Unknown status

PneumoniaPhase 1

Recruiting

Competition

Competitive Landscape

155 competitors in Pneumonia

#DrugCompanyPhaseTrials

Drug therapy

MMassachusetts General Hospital

Phase 2

1 2

Prevacid

Takeda

Preclinical

1 3

Plaquenil

Jazz Pharmaceuticals

Preclinical

1 4

Innohep

Jazz Pharmaceuticals

Preclinical

1 5

Retrovir

BBp Consulting, Inc

Preclinical

2 6

Primsol

CConrado Roberto Hoffmann Filho

Preclinical

2 7

Zantac 150

CChattem

Preclinical

2 8

Pepcid

KKenvue Brands

Preclinical

1 9

Aciphex

Akero Therapeutics

Preclinical

1 10

Protonix

WWyeth-Lederle Vaccines

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 2Recruiting

Elderly Patients

NCT06758037

Q2 2028

Phase 1Recruiting

Pneumonia

NCT06693362

Q2 2034

Recruiting

CAR

NCT06031610

Clinical

Trials by Indication[1]

Neuromodulation1 trial

The Role of Neuromodulation Technique In Depression Disorder

Unknown status·SShanghai Mental Health Center·N/A·NCT05047159·450 enrolled

Adolescent1 trial

Cognitive Behavioral Therapy for Depression Relapse Prevention in Children and Adolescents

Completed·UUniversity of Texas Southwestern Medical Center·N/A·NCT00158301·72 enrolled

Attention Deficit Hyperactivity Disorder1 trial

Cognitive Behavioral Therapy for Adult Attention Deficit Hyperactivity Disorder

Completed·MMassachusetts General Hospital·Phase 1·NCT00050050·40 enrolled

Pneumonia1 trial

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Evaluate the Safety and Efficacy of Uterine Blood Mesenchymal Stem Cells Injection for the Treatment of Severe Pneumonia Caused by Viruses

Recruiting·RRuijin Hospital·Phase 1·NCT06693362·60 enrolled

Benign Prostatic Hyperplasia1 trial

Prostatic Artery Embolization Versus Medical Treatment in Symptomatic Benign Prostatic Hyperplasia

Completed·AAssistance Publique - Hôpitaux de Paris·Phase 3·NCT02869971·90 enrolled

5 more indications

Neuroendocrine Carcinoma1 trial

Camrelizumab Combined With Chemotherapy for Recurrent or Advanced Cervical Neuroendocrine Carcinomas

Unknown status·LLei Li·Phase 2·NCT04635956·20 enrolled

Elderly Patients1 trial

Clinical Study of HiR+X Therapy for Newly Diagnosed Elderly Patients with DLBCL Intolerant to Chemotherapy

Recruiting·FFirst Affiliated Hospital of Ningbo University·Phase 2·NCT06758037·50 enrolled

Encephalopathy1 trial

Early Diagnosis and Timely Treatment of Cirrhotic Patients With Minimal Hepatic Encephalopathy (CHESS-NCRCID 2106)

Unknown status·HHepatopancreatobiliary Surgery Institute of Gansu Province··NCT05140837·10,000 enrolled

CAR1 trial

Revascularization Effect on CSVD Burden in Carotid Artery Stenosis

Recruiting·ZZhejiang Provincial People's Hospital··NCT06031610·1,000 enrolled

Ischemic stroke1 trial

Predictors and Prognostic Factors on the Acute Ischemic Stroke

Terminated·TTongji Hospital··NCT03122002·1,200 enrolled

Sources

References

[1]
ClinicalTrials.gov — 10 trial records for Drug therapy. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Drug therapy compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Drug therapy. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Massachusetts General Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: MMassachusetts General Hospital

Drug therapy

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Q2 2028

Q2 2034

Trials by Indication[1]

Neuromodulation1 trial

Adolescent1 trial

Attention Deficit Hyperactivity Disorder1 trial

Pneumonia1 trial

Benign Prostatic Hyperplasia1 trial

Neuroendocrine Carcinoma1 trial

Elderly Patients1 trial

Encephalopathy1 trial

CAR1 trial

Ischemic stroke1 trial

References

Drug Info

Quick Facts

Related News